Acute myeloid leukemia and novel biological treatments: Monoclonal antibodies and cell-based gene-modified immune effectors

Immunology Letters

Volumn 155, Issue 1-2, 2013, Pages 43-46

  Tettamanti, Sarah ^a   Magnani, Chiara Francesca ^a   Biondi, Andrea ^a   Biagi, Ettore ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Acute myeloid leukemia (AML); Chimeric antigen receptor (CAR); Cytokine induced killer (CIK) cells; Gene therapy; Immunotherapy; Monoclonal antibody (mAb)

Indexed keywords

ANTINEOPLASTIC AGENT; BLINATUMOMAB; CD135 ANTIGEN; CD33 ANTIGEN; CD44V6 ANTIGEN; CSL 360; CYTOTOXIC AGENT; DT 388 IL3; GEMTUZUMAB OZOGAMICIN; IMC EB10; LEUKEMIA ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ANTIBODY ENGINEERING; ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CELL BASED GENE THERAPY; DONOR LYMPHOCYTE INFUSION; DRUG TARGETING; DRUG WITHDRAWAL; EFFECTOR CELL; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ACT; ACUTE MYELOID LEUKEMIA; ACUTE MYELOID LEUKEMIA (AML); ADCC; ADOPTIVE CELL THERAPY; AML; ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY; BI-SPECIFIC T-CELL ENGAGERS; BITE; CAR; CDC; CHIMERIC ANTIGEN RECEPTOR (CAR); CHIMERIC ANTIGEN RECEPTORS; CIK; COMPLEMENT-DEPENDENT CYTOTOXICITY; CYTOKINE-INDUCED KILLER; CYTOKINE-INDUCED KILLER (CIK) CELLS; DLI; DONOR LYMPHOCYTE INFUSION; EFS; EVENT-FREE SURVIVAL; GENE THERAPY; GENTUZUMAB OZOGAMICIN; GMP; GO; GOOD MANUFACTURING PRACTICE; GRAFT VERSUS HOST DISEASE; GRAFT VERSUS LEUKEMIA; GVHD; GVL; HEMATOPOIETIC STEM/PROGENITOR CELLS; HSPCS; IMMUNOTHERAPY; LEUKEMIC STEM CELL; LSC; MAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY (MAB); NATURAL KILLER; NK; NOD/SCID/IL2R-ΓNULL; NSG; OS; OVERALL SURVIVAL; SB; SLEEPING BEAUTY; TAA; TUMOR ASSOCIATED ANTIGENS;

ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; RISK ASSESSMENT;

EID: 84887820522     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.09.013     Document Type: Review

References (41)

1. Dohner H., Estey E.H., Amadori S., Appelbaum F.R., Buchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
2. Creutzig U., van den Heuvel-Eibrink M.M., Gibson B., Dworzak M.N., Adachi S., de Bont E., et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 2012, 120:3187-3205.
3. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
4. Eppert K., Takenaka K., Lechman E.R., Waldron L., Nilsson B., van Galen P., et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011, 17:1086-1093.
5. FitzGerald D.J., Wayne A.S., Kreitman R.J., Pastan I. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res 2011, 71:6300-6309.
6. Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene 2011, 30:1009-1019.
7. Kikushige Y., Shima T., Takayanagi S., Urata S., Miyamoto T., Iwasaki H., et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 2010, 7:708-717.
8. Hamann P.R., Hinman L.M., Hollander I., Beyer C.F., Lindh D., Holcomb R., et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002, 13:47-58.
9. Candoni A., Martinelli G., Toffoletti E., Chiarvesio A., Tiribelli M., Malagola M., et al. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. Leuk Res 2008, 32:1800-1808.
10. Petersdorf S., Kopecky K., Stuart R.K. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 2009, 114(abstr 790):326.
11. Castaigne S., Pautas C., Terre C., Raffoux E., Bordessoule D., Bastie J.N., et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012, 379:1508-1516.
12. Burnett A.K., Russell N.H., Hills R.K., Kell J., Freeman S., Kjeldsen L., et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012, 30:3924-3931.
13. Kaspers G.J., Zimmermann M., Reinhardt D., Gibson B.E., Tamminga R.Y., Aleinikova O., et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol 2013, 31:599-607.
14. Topp M.S., Gokbuget N., Zugmaier G., Degenhard E., Goebeler M.E., Klinger M., et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012, 120:5185-5187.
15. Aigner M., Feulner J., Schaffer S., Kischel R., Kufer P., Schneider K., et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 2013, 27:1107-1115.
16. Walter R.B., Appelbaum F.R., Estey E.H., Bernstein I.D. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012, 119:6198-6208.
17. Jordan C.T., Upchurch D., Szilvassy S.J., Guzman M.L., Howard D.S., Pettigrew A.L., et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000, 14:1777-1784.
18. Jin L., Lee E.M., Ramshaw H.S., Busfield S.J., Peoppl A.G., Wilkinson L., et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009, 5:31-42.
19. Roberts A.W., He S., Bradstock K.F.M.S.H., Durrant S.T.S., Ritchie D.S. A phase 1 and correlative biological study of CSL360 (anti-CD123 mAb) in AML. Blood (ASH Annual Meeting Abstracts) 2008, 112:2956.
20. Frankel A., Liu J.S., Rizzieri D., Hogge D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma 2008, 49:543-553.
21. Stein C., Kellner C., Kugler M., Reiff N., Mentz K., Schwenkert M., et al. Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Br J Haematol 2010, 148:879-889.
22. - phenotype of the leukemia stem cell population. J Nucl Med 2011, 52:1465-1473.
23. Piloto O., Nguyen B., Huso D., Kim K.T., Li Y., Witte L., et al. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Res 2006, 66:4843-4851.
24. Hofmann M., Grosse-Hovest L., Nubling T., Pyz E., Bamberg M.L., Aulwurm S., et al. Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia. Leukemia 2012, 26:1228-1237.
25. Frey N.V., Porter D.L. Graft-versus-host disease after donor leukocyte infusions: presentation and management. Best Pract Res Clin Haematol 2008, 21:205-222.
26. Gross G., Waks T., Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 1989, 86:10024-10028.
27. Maher J. Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol 2012, 2012:278093.
28. Fischbach M.A., Bluestone J.A., Lim W.A. Cell-based therapeutics: the next pillar of medicine. Sci Transl Med 2013, 5:179ps177.
29. Peinert S., Prince H.M., Guru P.M., Kershaw M.H., Smyth M.J., Trapani J.A., et al. Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther 2010, 17:678-686.
30. Casucci M., Nicolis di Robilant B., Falcone L., Camisa B., Genovese P., Gentner B., et al. Co-expression of a suicide gene in CAR-redirected T cells enables the safe targeting of CD44v6 for leukemia and myeloma eradication. Blood ASH 2013.
31. Rupp U., Schoendorf-Holland E., Eichbaum M., Schuetz F., Lauschner I., Schmidt P., et al. Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study. Anti-cancer drugs 2007, 18:477-485.
32. Linn Y.C., Hui K.M. Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol 2010, 2010:435745.
33. Introna M., Borleri G., Conti E., Franceschetti M., Barbui A.M., Broady R., et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 2007, 92:952-959.
34. Introna M., Algarotti A., Micò C., Grassi A., Pievani A., Borleri G., et al. A Phase II study of sequential administration of DLI and Cytokine Induced Killer (CIK) cells in patients with hematologic malignancies relapsing after allogeneic hematopoietic stem cell transplantation: preliminary results. Blood (ASH Annual Meeting Abstracts) 2011, 118:657.
35. Marin V., Pizzitola I., Agostoni V., Attianese G.M., Finney H., Lawson A., et al. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica 2010, 95:2144-2152.
36. Tettamanti S., Marin V., Pizzitola I., Magnani C.F., Giordano Attianese G.M., Cribioli E., et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol 2013, 161:389-401.
37. Hackett P.B., Largaespada D.A., Switzer K.C., Cooper L.J. Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res 2013, 161:265-283.
38. Heslop H.E. Safer CARS. Mol Ther 2010, 18:661-662.
39. Di Stasi A., Tey S.K., Dotti G., Fujita Y., Kennedy-Nasser A., Martinez C., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011, 365:1673-1683.
40. Turatti F., Figini M., Balladore E., Alberti P., Casalini P., Marks J.D., et al. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J Immunother 2007, 30:684-693.
41. Hombach A.A., Schildgen V., Heuser C., Finnern R., Gilham D.E., Abken H. T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J Immunol 2007, 178:4650-4657.